Purple biotech to present additional mechanism of action data for nt219 at american association of cancer research 2021 annual meeting

Tel aviv, israel, march 11, 2021 (globe newswire) -- purple biotech ltd. (“purple biotech” ”, or the “company”) (nasdaq/tase: ppbt), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced that additional preclinical data supporting the mechanism of action of nt219, a dual inhibitor, novel small molecule that simultaneously targets irs1/2 and stat3, will be presented in a poster at the american association of cancer research (aacr) 2021 annual meeting, taking place in virtual format, on april 10-15 and may 17-21, 2021.  these updated data expand on the previously reported results generated from the company's collaboration with professor ido wolf, head of the oncology division, tel aviv sourasky medical center, and will be highlighted in a presentation titled, “adaptation of colorectal cancer cells to the brain microenvironment: the role of irs2.”
PPBT Ratings Summary
PPBT Quant Ranking